Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis

Valeria D’Ovidio ¹, Donatella Meo, Angelo Viscido, Giampaolo Bresci, Piero Vernia, Renzo Caprilli, World J Gastroenterol. 2011 Apr 14;17(14):1831-5.

GMA may be a valid therapeutic option for steroid-dependent ulcerative colitis patients with mild-moderate disease and its clinical efficacy seems to persist for 12 months.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080717/pdf/WJG-17-1831.pdf

https://pubmed.ncbi.nlm.nih.gov/21528055/